Evidence map›Paper›PMID 33358150›Full record

ArticleClinical genitourinary cancer2021

Small Cell Bladder Cancer Response to Second-line and Beyond Checkpoint Inhibitor Therapy: Retrospective Experience.

Jean Hoffman-Censits, Woonyoung Choi, Trinity J Bivalacqua, Philip Pierorazio, Max Kates, Kara Lombardo, Vamsi Parini, David McConkey, Edouard J Trabulsi, Noah Hahn and 1 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical genitourinary cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Jean Hoffman-CensitsThe Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD. Electronic address: jhoffm57@jhmi.edu.
Woonyoung ChoiThe James Buchanan Brady Urological Institute and Department of Urology, Baltimore, MD.
Trinity J BivalacquaThe James Buchanan Brady Urological Institute and Department of Urology, Baltimore, MD.
Philip PierorazioThe James Buchanan Brady Urological Institute and Department of Urology, Baltimore, MD.
Max KatesThe James Buchanan Brady Urological Institute and Department of Urology, Baltimore, MD.
Kara LombardoThe James Buchanan Brady Urological Institute and Department of Urology, Baltimore, MD.
Vamsi PariniDepartment of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD.
David McConkeyThe James Buchanan Brady Urological Institute and Department of Urology, Baltimore, MD.
Edouard J TrabulsiDepartment of Urology, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA.
Noah HahnThe Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD.
Andres MatosoDepartments of Pathology, Urology and Oncology, Johns Hopkins Medical Institutions, Baltimore, MD.

Funding

Opportunities for Pathology Trainees in Cancer ResearchT32CA193145 · NCI · JOHNS HOPKINS UNIVERSITY · PI ANDERS, ROBERT A., EBERHART, CHARLES G · 2015 to 2025
$2.6M
NCI NIH HHS T32 CA193145
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Urinary Bladder NeoplasmsAntibodies, MonoclonalHumansImmunotherapyNivolumabRetrospective StudiesAntibodies, MonoclonalNivolumabImmunotherapyNeuroendocrine cancerPlatinum refractory cancerUpper tractVariant histology

Identifiers

PMID33358150
PMCPMC9281535

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.